2CBCB-NBOMe


2CBCB-NBOMe, or NBOMe-TCB-2, is a receptor modulator">receptor (biochemistry)">receptor modulator and cyclized phenethylamine. It is the NBOMe derivative of the psychedelic drug TCB-2.

Pharmacology

Pharmacodynamics

2CBCB-NBOMe acts as a potent and selective agonist of the serotonin 5-HT2A and 5-HT2C receptors, with an affinity of 0.27nM at the human serotonin 5-HT2A receptor, similar to that of other drugs such as TCB-2, 25I-NBOMe, and Bromo-DragonFLY.

History

2CB2CB-NBOMe was first described in the scientific literature by the lab of David E. Nichols and colleagues in 2007. It was part of an ongoing research program focused on mapping of the specific amino acid residues responsible for ligand binding to the serotonin 5-HT2A receptor.

Society and culture

Legal status

Canada

2CBCB-NBOMe is not a controlled substance in Canada as of 2025.

United States

2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.